IRD (Opus Genetics, Inc.) Stock | Pipeline, Insider Trades & Financials

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Opus Genetics, Inc.

$4.04

+0.13 (+3.32%)

C 45Pipeline Score Fair Value Pharma · Clinical

Market Cap

346.75 M

EPS

-1.35

P/E Ratio

Value Trade

3.75 M

SEC Financials

Q1 2026

Dilution Risk
25%
Revenue
2.16 M
R&D Expenses
10.58 M
Operating CF
-12.73 M

Total Assets
66.79 M
Total Liabilities
87.89 M
Equity
-45.84 M
D/E Ratio
12,345

-12.88 %

Week

-19.32 %

1 Month

18.01 %

3 Month

120.73 %

6 Month

-7.19 %

5 Year

-100 %

All Time

Cash Data

Stable

Cash Position
59.96 M
Monthly Burn
4.24 M
Runway
13.1 mo
Burn Trend
Accelerating
SEC Filing
May 12, 2026

Overview

Volume

689.97 K

52 Week Range

0.90 - 5.81

% held by Insiders

18.93 %

% held by Institutions

51.27 %

Enterprise Value

312.72 M

Total Shares

71.10 M

Short %

6.98 %

Float Shares

56.10 M

Company Description

HQ: 8 DAVIS DRIVE, DURHAM, NC, 277...

Employees:28

https://www.opusgtx.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
Phase 1/2 topline data readout example	OPGx-LCA5 Leber congenital amaurosis (LCA)	Phase 1/2	—	Subscribe to access the data.	Gene Therapies	Ophthalmologic System
Phase 1/2 topline data readout example	OPGx-LCA5 Leber congenital amaurosis (LCA)	Phase 1/2	—	Subscribe to access the data.	Gene Therapies	Ophthalmologic System
Phase 1/2 topline data readout example	OPGx-LCA5 Leber congenital amaurosis (LCA)	Phase 1/2	—	Subscribe to access the data.	Gene Therapies	Ophthalmologic System

Unlock Upcoming Catalyst data

Drug Pipeline Intelligence

C45

Pipeline Score

$415M

Pipeline Value

Fair Value

Valuation Signal

Drugs Scored

1.2x

rNPV / MCap

Top 63%

Micro Cap

(rank 336 of 905)

Percentile Rank

Opus Genetics, Inc. carries a moderate pipeline score (45/100), with $1.8B risk-adjusted pipeline value, led by APX3330 in Diabetic Retinopathy (Phase 2).

Showing 1 of 1 assets

Drug	Indication	Phase	NCT ID	PTRS	rNPV	Status	Enrollment	Velocity	Design	Completion	ML Signal	Last Change
APX3330 Small molecule	Diabetic Retinopathy	Phase 2	NCT04692688	29%	$611M	COMPLETED	103	-	-	Jan 25, 2023	-	Feb 27, 2023

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
Phentolamine Ophthalmic Solution 0.75%	presbyopia	Phase 3	2025-06-26	27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieved a ≥15-letter improvement in binocular distance-corrected near visual acuity (DCNVA) at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p<0.0001).,20.6% of patients in the Phentolamine arm achieved ≥15-letter ETDRS (≥3-line) gain in DCNVA at 1-hour post-dose on Day 1 compared to 6.1% of those receiving placebo (p=0.0002).,Significant patient-reported functional benefit at Days 3 and 8 and Week 6 were observed with patients reporting satisfaction with near vision upon awakening (p<0.0001) and improvement in their near vision (p<0.0001).,No evidence of tachyphylaxis was observed after 6 weeks compared to the primary endpoint at Day 8 12 hours post-dose.	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia Read More
Phentolamine Ophthalmic Solution 0.75%	presbyopia	Phase 3	2025-06-26	27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieved a ≥15-letter improvement in binocular distance-corrected near visual acuity (DCNVA) at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p<0.0001).,20.6% of patients in the Phentolamine arm achieved ≥15-letter ETDRS (≥3-line) gain in DCNVA at 1-hour post-dose on Day 1 compared to 6.1% of those receiving placebo (p=0.0002).,Significant patient-reported functional benefit at Days 3 and 8 and Week 6 were observed with patients reporting satisfaction with near vision upon awakening (p<0.0001) and improvement in their near vision (p<0.0001).,No evidence of tachyphylaxis was observed after 6 weeks compared to the primary endpoint at Day 8 12 hours post-dose.	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia Read More
Phentolamine Ophthalmic Solution 0.75%	presbyopia	Phase 3	2025-06-26	27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieved a ≥15-letter improvement in binocular distance-corrected near visual acuity (DCNVA) at 12 hours post-dose on Day 8, compared to 11.5% of patients on placebo (p<0.0001).,20.6% of patients in the Phentolamine arm achieved ≥15-letter ETDRS (≥3-line) gain in DCNVA at 1-hour post-dose on Day 1 compared to 6.1% of those receiving placebo (p=0.0002).,Significant patient-reported functional benefit at Days 3 and 8 and Week 6 were observed with patients reporting satisfaction with near vision upon awakening (p<0.0001) and improvement in their near vision (p<0.0001).,No evidence of tachyphylaxis was observed after 6 weeks compared to the primary endpoint at Day 8 12 hours post-dose.	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in IRD

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

Biotech Analyst Ratings

Symbol

Firm

Rating

Action

Price Target

Upside

date

IRD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

IRD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

IRD

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

Unlock Biotech Analyst Ratings data

IRD Stock Forecast & Analyst Consensus

BUY

Analyst Ratings

Buy65.0%

Hold25.0%

Sell10.0%

Price Target Trend

Average$24.00

Low$18.00

High$32.00

Unlock Price Target Trend

IRD Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv
2026-11-20			0.00			0	-	-	-	-	-	-
2026-11-20			0.00			0	-	-	-	-	-	-
2026-11-20			0.00			0	-	-	-	-	-	-

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Latest Opus Genetics, Inc. (IRD) News & Alerts

Saturday, June 13, 2026

(%)

+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

How IRD ranks across every disease it competes in

Show observational/device entries

Indication	Rank	Phase	Best Drug	Top 3 Competitors	Market $B	LoA	Position
Eye Disorders	#4 of 9	PHASE 3	0.75% Phentolamine	SGP HROW PRQR	—	0	CONTENDER
Hypertension	#8 of 16	PHASE 1	OPGx-BEST1	LLY ALNY MLYS	$9.41B	0.76	FOLLOWER
Rare Genetic Disorders	#53 of 61	PHASE 1	OPGx-BEST1	BMRN ASND NVS	—	0.81	FOLLOWER

Recent Updates

Recently added Catalysts

$4.04

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in IRD

Biotech Analyst Ratings

IRD Stock Forecast & Analyst Consensus

IRD Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest Opus Genetics, Inc. (IRD) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

Indication landscape

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$4.04

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in IRD

Biotech Analyst Ratings

IRD Stock Forecast & Analyst Consensus

IRD Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest Opus Genetics, Inc. (IRD) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position